FAKTOR RISIKO ACUTE KIDNEY INJURY (AKI) PADA PASIEN DENGAN KEGANASAN
RISK FACTORS FOR ACUTE KIDNEY INJURY (AKI) IN PATIENTS WITH MALIGNANCY
Abstract
Acute kidney injury (AKI) merupakan kondisi dimana seseorang mengalami penurunan fungsi ginjal secara tiba-tiba (<48 jam). Mereka dengan AKI mengalami peningkatan kadar serum kreatinin >0.3 mg/dl, kenaikan presentasi kreatinin serum ≥50% (1,5 kali dari nilai awal/normal), atau penurunan urine output. Penelitian sebelumnya menunjukkan bahwa AKI merupakan komplikasi umum dari kanker, dimana hampir separuh pasien neoplastik mengalami AKI selama perjalanan penyakit mereka. Hal ini tentunya berdampak besar pada prognosis keseluruhan, lama rawat inap, dan biaya pengobatan. Kejadian AKI pada pasien kanker merupakan hal yang umum, dimana AKI seringkali ditemukan dalam perjalanan penyakit pasien dengan keganasan. AKI dapat disebabkan oleh karena faktor pasien, tumor, maupun pengobatan. Pencegahan dan antisipasi harus dilakukan untuk meningkatkan luaran pasien.
References
KDIGO CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.; 2013.
Aru W, Alwi I, Marcelus S, et al. Buku Ajar Ilmu Penyakit Dalam. 5 ed. (Soeroso J, Isbagio H, Kalim H, Broto R, Pramudiyo R, ed.). Interna; 2013.
Jameson J, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J. Harrison’s Principles of Internal Medicine 20th ed. New York NY, McGraw Hill Educ. Published online 2018.
Rewa O, Bagshaw SM. Acute kidney injury—epidemiology, outcomes and economics. Nat Rev Nephrol. 2014;10:193–207.
Meraz-Munoz A, Langote A, D Jhaveri K, Izzedine H, Gudsoorkar P. Acute Kidney Injury in the Patient with Cancer. Diagnostics (Basel, Switzerland). 2021;11(4). doi:10.3390/diagnostics11040611
Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38(3):295–308. doi:10.23876/j.krcp.19.042
Setiati S, Alwi I, Sudoyo AW, Sumadibrata M, Setiyohadi B, Syam AF. Buku Ajar Ilmu Penyakit Dalam. 6 ed. Interna Publishing; 2014.
Bilgil B, Haliloglu M, Cinel I. Sepsis and Acute Kidney Injury. Turk J Anaesthesiol Reanim. 2014;42(6):294–301.
Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399–406. doi:10.1016/j.ejim.2011.05.005
Cosmai L, Porta C, Foramitti M, et al. Preventive strategies for acute kidney injury in cancer patients. Clin Kidney J. 2021;14(1):70–83. doi:10.1093/ckj/sfaa127
Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 2015;11(6):354–370. doi:10.1038/nrneph.2015.15
Capasso A, Benigni A, Capitanio U, et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int. 2019;96(3):555–567.
Finlay S, Bray B, Lewington AJ, et al. Identification of risk factors associated with acute kidney injury in patients admitted to acute medical units. Clin Med (Northfield Il). 2013;13(3):233.
Canet E, Vincent F, Darmon M, Soares M. Acute kidney injury in hematological patients. Curr Opin Crit Care. 2015;21(6):549–558.
Shah M, Perazella MA. AKI in multiple myeloma: paraproteins, metabolic disturbances, and drug toxicity. J Onco-Nephrology. 2017;1(3):188–197.
McDougal W, Wein A, Kavoussi L. Campbell-Walsh Urology. 4 ed. Elsevier; 2016.
Gupta S, Gudsoorkar P, Jhaveri KD. Acute Kidney Injury in Critically Ill Patients with Cancer. Clin J Am Soc Nephrol. Published online Maret 2022:CJN.15681221. doi:10.2215/CJN.15681221
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–124.
Shah R, Xia C, Krailo M, et al. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecol Oncol. 2018;150(2):253–260. doi:10.1016/j.ygyno.2018.05.025
Volarevic V, Djokovic B, Jankovic MG, et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 2019;26(1):1–14.
Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
Kumar N, Shirali AC. What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: high-flux hemodialysis or carboxypeptidase G2? In: Seminars in dialysis. Vol 27. ; 2014:226–228.
Howard SC, Jones DP, Pui CH. The Tumor Lysis Syndrome. N Engl J Med. 2011;364(19):1844–1854.
Copyright (c) 2024 Agustiawan, Ekawaty Suryani Mastari, Tivalen Dwirara Anggraini , Ulfah Octavia Saragih
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
